WAVE Life Sciences (NASDAQ:WVE – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.
Valuation & Earnings
This table compares WAVE Life Sciences and Aligos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| WAVE Life Sciences | $42.73 million | 11.82 | -$204.38 million | ($1.07) | -2.39 |
| Aligos Therapeutics | $2.19 million | 3.48 | -$24.19 million | ($6.35) | -0.19 |
Profitability
This table compares WAVE Life Sciences and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| WAVE Life Sciences | -296.86% | -44.66% | -36.80% |
| Aligos Therapeutics | -197.01% | -206.30% | -99.45% |
Institutional and Insider Ownership
89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
WAVE Life Sciences has a beta of -1.4, meaning that its share price is 240% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.43, meaning that its share price is 143% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings for WAVE Life Sciences and Aligos Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| WAVE Life Sciences | 1 | 2 | 15 | 2 | 2.90 |
| Aligos Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
WAVE Life Sciences currently has a consensus price target of $20.44, suggesting a potential upside of 698.61%. Aligos Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 3,055.74%. Given Aligos Therapeutics’ higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than WAVE Life Sciences.
Summary
WAVE Life Sciences beats Aligos Therapeutics on 10 of the 14 factors compared between the two stocks.
About WAVE Life Sciences
WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.
About Aligos Therapeutics
Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.
Receive News & Ratings for WAVE Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
